Revolutionary point-of-care, affordable early detection Lung cancer and Tuberculosis diagnostics
EARLY BIRD TERMS: $31,125 LEFT
$168,875
raised from 120 investors
INVEST
min $200
INVESTMENT TERMS
$20M
$18M
valuation cap
Future Equity
Early Bird Bonus:
The first $200K of investments will be in a SAFE with a $18M valuation cap and 20% discount
$500,
$1K,
$5K,
$20K
A Future Equity Agreement (SAFE) gives you the right to future shares in the company. If you invest, you're betting the company will be worth more than $18M eventually.
I have learnt that Pace Diagnostics and their team have worked for many years to develop their comprehensive portfolio of point-of-care rapid diagnostics that can provide quick result with simple steps, minimally invasive, and no expert/lab dependent. Since the tests are affordable and accessible, we can use them for mass population testing, therefore, more people can be tested and save lives. Pace Diagnostics are passionate about their science, their innovative products, their saving lives mission, and their investors. I am especially attracted to their positive social impact goal – save millions of lives, at the same time, I am impressed with the enormous financial opportunity for their investors – these are billions USD market sizes for TB and Lung Cancer diagnostics. It is great news for the investors who are enthusiastic about helping others and concurrently, receive positive financial upside.
